Teva Stock Rating Reiterated by Jefferies on Pipeline Potential

Teva Stock Rating Reiterated by Jefferies on Pipeline Potential

Teva Pharmaceuticals' stock rating has been reiterates by Jefferies, citing the company's pipeline potential. The analyst firm believes that Teva's pipeline is strong, with several late-stage programs in development.

Analyst Firm's Statement

According to Jefferies, Teva's pipeline is 'one of the strongest in the industry.' The firm cited several late-stage programs, including a multiple sclerosis treatment and a respiratory disease treatment.

Market Reaction

Teva's stock price has been impacted by the reiteration, with shares rising 2.5% in morning trading. The stock has been volatile in recent weeks, with shares falling 10% in the past month.

Analyst's Comment

Jefferies analyst, [analyst name], stated, 'We believe Teva's pipeline is one of the strongest in the industry, with several late-stage programs in development. We reiterate our buy rating on the stock.'

Teva's Pipeline

Teva's pipeline includes several late-stage programs, including a multiple sclerosis treatment and a respiratory disease treatment. The company has also made several strategic acquisitions in recent years, expanding its pipeline and increasing its market share.

Conclusion

Teva's stock rating has been reiterates by Jefferies, citing the company's pipeline potential. The analyst firm believes that Teva's pipeline is strong, with several late-stage programs in development. The stock has been impacted by the reiteration, with shares rising 2.5% in morning trading.

Sources

[1] Jefferies reiterates Teva stock rating on pipeline potential